Switch to:
More From Other Websites
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 15 2014
BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 04 2014
BioTime to Present at the LD Micro VII Conference Dec 03 2014
BIOTIME INC Financials Nov 15 2014
BIOTIME INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
BioTime Reports Third Quarter Results and Recent Progress Nov 10 2014
BIOTIME INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014
BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa... Nov 03 2014
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 03 2014
BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa... Nov 03 2014
Asterias Biotherapeutics to Report Third Quarter Results on November 10, 2014 Oct 31 2014
BIOTIME INC Files SEC form 8-K, Entry into a Material Definitive Agreement Oct 22 2014
Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of... Oct 20 2014
Bloomberg Advantage: ING’s Brzeski, BioTime CEO, Mayor Warren Oct 10 2014
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Oct 09 2014
BioTime, Inc. Closes $31 Million Financing Oct 09 2014
BioTime, Inc.’s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer... Sep 15 2014
BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology... Sep 11 2014
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer... Jul 14 2014
BioTime To Present at Regen Med Investor Day March 26 in New York Mar 25 2014
BioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate... Mar 17 2014
BioTime Provides Financing and Product Development Update Mar 03 2014
BioTime Provides Financing and Product Development Update Mar 03 2014
BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit Feb 18 2014
BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer... Jan 27 2014
BioTime’s Subsidiary LifeMap Sciences Announces Release of LifeMap Discovery™ Version 1.5 with... Jan 17 2014
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded... Jan 02 2014
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s... Dec 23 2013
BioTime Reports Isolation of Novel Brain-Associated Cells From Human Embryonic Stem Cells Dec 20 2013


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK